Compare AbCellera Biologics Inc (ABCL) vs Coupang Inc (CPNG) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

Coupang (CPNG) trades at $18.53, showing minimal daily movement (-0.16%) amid mixed technical signals. The stock maintains bullish moving averages but faces resistance near $20. Fundamentally, revenue growth remains strong at $34.53B (2025) though profitability is inconsistent with recent quarterly EPS misses. Regulatory challenges emerged with a $409 million data breach fine in June 2026, though investor sentiment improved as the penalty was below worst-case fears.

Wall Street maintains strong bullish consensus (87.5% buy ratings) with a $25.80 price target implying 39% upside. Key opportunities include sustained e-commerce growth and operational cash flow strength ($1.77B in 2025), while risks center on regulatory scrutiny, competitive pressures, and volatile profitability. The stock's high P/E (184.18) requires continued execution to justify valuation.